Get startedLog in
    Picture of Anebulo Pharmaceuticals logo

    ANEB — Anebulo Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Anebulo Pharmaceuticals Q2 net loss narrows

    Picture of Anebulo Pharmaceuticals logoAnebulo Pharmaceuticals
    12/02/2026 21:27
    Overview

Clinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mln

Company to voluntarily delist from Nasdaq, citing cost concerns

Operating expenses for fiscal Q2 remain flat at $2.6 mln

Outlook

Company plans to delist from Nasdaq by February 27, 2026

Result Drivers

OPERATING EXPENSES - Total operating expenses remained flat at $2.6 mln compared to the same period last year

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q2 EPS-$0.05
    Q2 Net Income-$2 mln
    Q2 Basic EPS-$0.05
    Q2 Operating Expenses$2.60 mln
    

Press Release: ID:nBw7zX9TDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Anebulo Pharmaceuticals

    See all news